SCHEMBL3240460

SCHEMBL3240460

CC1(C)C(=O)N(C2C3CC4CC(C3)CC2C4)N1C(=O)c1ccncc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 3/20 0.42
CHRNB4 P30926 3/20 0.42
CHRNA3 P32297 3/20 0.42
CHRNA4 P43681 3/20 0.42
GAA P10253 4/20 0.42
USP2 O75604 1/20 0.40
CHRNA7 P36544 2/20 0.38
NPC1 O15118 1/20 0.38
EPHX1 P07099 2/20 0.37
EPHX2 P34913 2/20 0.37
PIK3CD O00329 1/20 0.36
FLT3 P36888 1/20 0.36
GSK3B P49841 1/20 0.36
RECQL P46063 1/20 0.36
KDM4E B2RXH2 3/20 0.35
KMT2A Q03164 2/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2169090 0.87 USP2 (0.51) CHRNB2CHRNB4CHRNA3CHRNA4USP2
SCHEMBL2169195 0.86 PKM (0.40) GAAUSP2KMT2ACYP3A4CYP2C19
SCHEMBL13368830 0.86 USP2 (0.39) USP2EPHX2
SCHEMBL2183974 0.86 TSHR (0.43) CHRNB2CHRNB4CHRNA3CHRNA4USP2
SCHEMBL2170275 0.85 ALDH1A1 (0.40) USP2EPHX2KMT2ACYP3A4CYP2C19
SCHEMBL2170194 0.85 USP2 (0.38) USP2EPHX2CYP3A4CYP2C19
SCHEMBL2170348 0.85 USP2 (0.38) GAAUSP2NPC1KDM4EKMT2A
SCHEMBL2169179 0.85 KMT2A (0.39) USP2CHRNA7KMT2AMEN1ALDH1A1
SCHEMBL2168888 0.85 USP2 (0.38) USP2NPC1EPHX2KDM4EKMT2A
SCHEMBL2169755 0.84 MEN1 (0.39) GAAUSP2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed
WO-2010050191-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME 興和株式会社 (JP) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME HSD11B1, HSD11B2, HSD3B1 CHRNB2 1947/4885CHRNB4 2895/4885CHRNA3 1697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.